Worldwide, several million HTLV-I carriers are at risk for disease, with an estimated lifetime cumulative risk of 1%-5%. However, the determinants of disease progression are relatively unknown. We studied human leukocyte antigens (HLA class II) that have been implicated in the pathogenesis of HTLV-I-related diseases. Methods: We analyzed HLA class II alleles among asymptomatic HTLV-I carriers (n = 45), patients with ATL (n = 49) or HAM/TSP (n = 54), and HTLV-I seronegative control subjects (n = 51). All participants were of African descent and were enrolled in epidemiologic studies conducted at the University of the West Indies, Kingston, Jamaica. We used standard microlymphocytotoxicity assays for HLA antigen serotyping and polymerase chain reactionbased methods to examine HLA class II DRB1 and DQB1 alleles. Results: Two antigens determined by serotyping, DR15 and DQ1, occurred at significantly increased frequency among HTLV-I carriers compared with seronegative control subjects (42% versus 22% for DR15 [odds ratio {OR} = 2.7; 95% confidence interval {CI} = 1.0-
Human T-cell lymphotropic virus type I (HTLV-I) infection is associated with an increasing spectrum of diseases (1, 2) but is most definitively associated with adult T-cell leukemia/lymphoma (ATL), a rapidly, fatal T-cell lymphoma (3) , and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP), a chronic neurodegenerative disorder (4) . HTLV-I is endemic in southern Japan; the Caribbean; parts of South America, Africa, and the Middle East; and the Melanesian Islands. The virus has also been identified in areas within the United States and other parts of North America and Europe, particularly among immigrant populations from endemic areas (5) . HTLV-I-related diseases cluster in areas that are endemic for the virus. The annualized incidence of ATL and HAM/TSP, among major endemic populations, has been estimated as 16 and 22 cases in 100 000 HTLV-I carriers, respectively (6, 7) . It has been hypothesized that ATL develops after a long latent period of approximately 20-40 years following childhood infection primarily due to maternal transmission of HTLV-I via breast-feeding (3) . HAM/ TSP has been attributed predominantly to sexually or transfusion-acquired infection, with disease developing in days to years following infection (8, 9) . Determinants of the pathogenesis of these distinct disease entities are not clearly understood. However, the differential immune response to the virus among HTLV-I infected, asymptomatic carriers (AC) has been implicated.
Major histocompatibility complex (MHC), human leukocyte antigens (HLAs) class I (A, B, and C loci), and class II (DR and DQ loci) genes, located on chromosome 6, have a unique role in regulating the immune response to infection and malignant transformation (10, 11) . Experiments among inbred mice pioneered in the mid-1960s were among the first to show possible genetic control of the immune response by the MHC (12) . These studies recognized that specific MHC loci were linked to ability to mount an antibody response. Similar to this animal model, a human corollary is represented by the differential antibody response among patients with HTLV-Irelated disease, with patients with HAM/ TSP having elevated antibody levels compared with HTLV-I carriers and patients with ATL (13) . Additionally, Usuku et al. (14) have reported that host immunogenetic background, reflected by level of spontaneous lymphocyte proliferation, can be linked to HLA haplotypes that differ between patients with ATL and patients with HAM/TSP. HLA haplotypes associated with ATL are characterized by a low spontaneous lymphocyte proliferation response, while those of HAM/TSP represent high responders (15) . It is likely that similar host factors are important in other HTLV-I endemic populations, as suggested by preliminary studies conducted in Jamaica that reveal possible disease associations with particular HLA class II alleles (16) .
To confirm the role for HLA class II as an important host-related immunogenetic factor, we have examined in this report whether HLA class II alleles are associated with HTLV-I infection and its related disease outcomes, ATL and HAM/TSP, in a homogeneous Jamaican population of African descent.
Methods
Study population. Sera and lymphocyte specimens were collected from a population of healthy workers employed in the food handler industry in Jamaica. This population was previously described in a survey of the island-wide seroprevalence of HTLV-I in Jamaica conducted from 1984 through 1985 (17) . Among participants from the previous study, all HTLV-I seropositive and HTLV-I seronegative individuals from two parishes, Kingston and Clarendon, were re-visited from 1987 through 1988 and peripheral blood lymphocyte samples were obtained. We initially selected 100 food handlers for the current analysis. The participants chosen were of African descent with known HTLV-I status, who were otherwise designated without regard to other factors. Two individuals were subsequently deleted because their race was not correctly classified. Two additional samples were deleted because of insufficient DNA for typing. Final analysis was reported for 96 of the 100 individuals, 45 who were HTLV-I seropositive (47%) and 51 who were HTLV-I seronegative (53%). Sera and lymphocyte specimens were also evaluated from unrelated subjects with clinically and/or pathologically characterized ATL (n ‫ס‬ 49) and HAM/TSP (n ‫ס‬ 54), who were enrolled in case registries maintained at the University of the West Indies, Kingston, Jamaica. All patients were participants in epidemiologic studies (3, 9, 18) approved by the Human Subjects Review Committees at the University of the West Indies and the National Cancer Institute, Bethesda, MD. All individuals with ATL and HAM/TSP were HTLV-I seropositive.
Laboratory procedures. HTLV-I serologic status was determined in sera by enzyme-linked immunosorbent assay (ELISA; E. I. Du Pont de Nemours Company, Wilmington, DE, or Genetic Systems, Seattle, WA) and confirmed with western blot (Cambridge-Biotech, Rockville, MD). Antibody titers were determined for all HTLV-I seropositive carrier samples by end-point-dilution ELISA testing with fourfold dilutions. Heparinized whole blood samples were obtained and peripheral blood lymphocytes were separated by Ficoll-Hypaque density gradient centrifugation at 2100 rpm/900g (19) . Peripheral blood lymphocytes were stored at −70°C in a liquid nitrogen freezer until used. Serologic typing for HLA was performed on HTLV-I carriers and seronegative control subjects using the cryopreserved cells by the standard antibody-mediated National Institutes of Health microlymphocytotoxicity test (20) with qualified HLA trays containing 213 antisera for different HLA-A, -B, and -C antigens and 70 antisera for different HLA-DR and -DQ antigens. All sera were exchanged with reference laboratories and standardized to the assignment of the 11th (1991) International Histocompatibility Workshop (21) . DNA typing for HLA class II alleles (DRB1 and DQB1) was performed on all HTLV-I carriers, ATL and HAM/TSP cases by polymerase chain reaction (PCR) on DNA extracted from cryopreserved cells using PCR sequence-specific oligonucleotides (ELPHA-Biotest; Biotest Diagnostics Corp., Dreieich, Germany) or PCR restriction-fragment-length polymorphisms (SMITEST; Sumitomo Metal Industries, Ltd., Tokyo, Japan). All HLA typing (serology, microcytotoxicity, and PCR assays) was performed in the laboratory of S. Sonoda at Kagoshima University in Japan.
Statistical analysis. HLA data were analyzed to evaluate a possible association of class II alleles with HTLV-I infection, ATL, or HAM/TSP. HLA class II antigen (DR and DQ) and allele (DRB1 and DQB1) frequencies were calculated and comparisons were made with chi-squared (likelihood ratio [G] test) (22) and Fisher's exact test (23) to detect an association of a specific allele with HTLV-I infection or related disease, using Statistical Analysis Software Program (SAS Institute, Cary, NC). All P values reported were two-tailed, with significance defined as P<.05. When case groups were found to be significantly different from control subjects, the odds ratio (OR) with 95% confidence interval (CI) associated with specific class II alleles was calculated. To eliminate the possibility that significant associations were due to chance because multiple comparisons of antigens/alleles between groups were made concurrently, the data were adjusted by the omnibus chi-squared [G] test (22) . If this test was significant, it suggested a statistical difference in the frequencies at the locus tested. When this global test showed no significance, a Bonferroni's correction was performed for the individual antigens/alleles showing a significant difference (24) . Additionally, we tested an a priori hypothesis for specific significant alleles by comparing our findings with those reported in the literature for another HTLV-I endemic population group. Linkage disequilibrium between two alleles in different loci was also evaluated (25) . HTLV-I antibody geometric mean titers were calculated by taking the mean of the log of the actual titer value. The Student's t test was used to examine the significance of a difference between two means.
Results

HLA and HTLV-I Infection
The HTLV-I carrier and seronegative control groups were homogeneous with respect to sociodemographic data. The median age was 45 years in both groups. Eighty-two percent of both the HTLV-Ipositive and HTLV-I-negative subjects were female, which was consistent with the larger population from which samples were drawn. The majority of study participants (89% of HTLV-I-positive and 82% of HTLV-I-negative subjects) were born outside of Kingston. Nearly every participant (100% of HTLV-I-positive and 96% of HTLV-I-negative subjects) had attended some school, although only a modest number had completed secondary education or higher (36% of HTLV-I-positive and 35% of HTLV-I-negative subjects). A slightly higher proportion of HTLV-I-positive (55%) compared with HTLV-I-negative (43%) individuals earned income at or above the minimum wage. Table 1 shows class II antigens with significant statistical differences between HTLV-I-positive and HTLV-I-negative subjects. Two class II antigens, DR15 and DQ1, were significantly higher among HTLV-I-positive subjects (OR ‫ס‬ 2.7; 95% CI ‫ס‬ 1.0-7.2 and OR ‫ס‬ 3.1; 95% CI ‫ס‬ 1.2-8.5, respectively). Even after applying the Bonferroni's adjustment for multiple comparisons, the elevation of the antigen DQ1 among HTLV-I-positive subjects was still significant. The increase of DR15 among HTLV-I-positive subjects was not significant by this conservative adjustment. However, these two antigens were found to be in linkage disequilibrium, with DR15 detected only in the presence of DQ1. The coefficient of disequilibrium was stronger among HTLV-I-positive (0.113) than HTLV-Inegative (0.078) subjects. DQ1 alone or in combination with DR15 was detected in 78% of HTLV-I-positive subjects compared with 53% of HTLV-I-negative subjects (P ‫ס‬ .01, P ‫ס‬ .049 with Bonferroni's correction).
To evaluate whether any of the antigens at higher frequency among HTLV-I positive carriers corresponded to a differential viral immune response, we measured HTLV-I antibody titers among seropositive subjects. We observed no difference in proportion of individuals having elevated titers above the median level (1 : 9886) for HTLV-I carriers with DR15-DQ1 haplotype (47%), DQ1 only (56%), or other antigens (50%). The geometric mean titer (GMT) was also calculated for these same groups and they did not differ. GMT among HTLV-I carriers was 1 : 12 599 for those with DR15-DQ1, 1 : 10 355 for those with DQ1 only, and 1 : 11 119 for HTLV-I carriers with other HLA-class II antigens.
HLA and HTLV-I-Associated Disease: ATL and HAM/TSP
Because HLA antigens among HTLV-I carriers differed from those in HTLV-I-negative control subjects, a comparison of HTLV-I carriers to patients with HTLV-I-related disease was conducted to identify HLA class II alleles among carriers that might be disease specific and predictive of subsequent development of ATL or HAM/TSP. HTLV-I carriers and patients with ATL and HAM/ TSP were DNA typed for HLA class II, DRB1 and DQB1 alleles ( Table 2) .
Since the HTLV-I carriers had been previously serotyped, there was an opportunity to directly compare serotyping with DNA typing for the significant alleles, D R 1 5 ( D R B 1 * 1 5 0 1 ) a n d D Q 1 (DQB1*0501,*0502,*05031,*0602,*0605, *0609). For HLA DR15, there was agreement between the two methods for each subject except one. Serologic typing misclassified DRB1*1601 (DR16) as DR15, both splits of the parent antigen DR2. For HLA DQ1, there was agreement between the two methods for each subject except one and another with missing results. Serologic typing misclassified DQB1*0201 (DQ2) as DQ1. DNA allele typing was able to exclude cross-reactive antibody patterns resulting from the serologic typing trays. The DNA allele typing was confirmed by linkage disequilibrium of DR-DQ alleles. Previous subjects with undetectable alleles with serologic typing were identifiable by use of DNA typing. None of the changes altered the statistical significance of the initial results shown in Table 1 .
HLA class II allele frequencies were similar between HTLV-I carriers and patients with ATL with no significant differences (Tables 2 and 3 ). In contrast, there were two DRB1 alleles with significantly greater frequency among HTLV-I carriers than patients with HAM/TSP, DRB1*1501 (OR ‫ס‬ 3.0; 95% CI ‫ס‬ 1.3-7.4) and DRB1*1101 (OR ‫ס‬ 3.4; 95% CI ‫ס‬ 0.94-15.4). One DQB1 allele had significantly greater frequency among HTLV-I carriers than patients with HAM/ TSP, DQB1*0602 (OR ‫ס‬ 3.0; 95% CI ‫ס‬ 1.5-6.4).
Comparisons of alleles between patients with ATL and HAM/TSP (Table 4) revealed that two DRB1 alleles had g r e a t e r f r e q u e n c y a m o n g A T L , DRB1*1101 (OR ‫ס‬ 4.3; 95% CI ‫ס‬ 1.3-18.6) and DRB1*1501 (OR ‫ס‬ 2.3; 95% CI ‫ס‬ 1.0-5.5). The HLA class II allele, DQB1*0602 was also significantly increased in frequency among patients with ATL compared with patients with HAM/ TSP (OR ‫ס‬ 2.3; 95% CI ‫ס‬ 1.1-4.7). The haplotypes DRB1*1101-DQB1*0301 and DRB1*1501-DQB1*0602 were significantly increased (P ‫ס‬ .01 and P ‫ס‬ .04, respectively) among patients with ATL compared with HAM/TSP. The haplotype *ATL ‫ס‬ adult T-cell leukemia/lymphoma; HAM/TSP ‫ס‬ HTLV-I-associated myelopathy/tropical spastic paraparesis.
†Unable to type DNA in two samples. ‡ 1 DRB1*1501-DQB1*0602 was also significantly increased (P ‫ס‬ .005) among HTLV-I carriers compared with patients with HAM/TSP. Several alleles were increased in frequency among HAM/TSP compared with HTLV-I carriers and ATL; however, they were not statistically significant.
HLA Among ATL and HAM/TSP in Jamaica and Japan
To determine whether these HLA alleles identified in other populations would confer susceptibility to HTLV-I and related disease, a comparison was made with findings reported among HTLV-I carriers and patients with HAM/TSP and ATL in Japan (Table 4 ) (26) . Although the candidate alleles were lower in frequency among the Japanese population compared with Jamaica, DRB1*1501 and DQB1*0602 were significantly increased among ATL compared with HAM/TSP patients and among HTLV-I carriers compared with HAM/TSP in both populations. The increased frequency of the DRB1*1101 allele among ATL compared with HAM/TSP patients was unique to Jamaica.
Discussion
Among HTLV-I carriers, only a small percentage (1%-5%) of individuals develop the HTLV-I related diseases, ATL or HAM/TSP (6, 27) . The major determinants of disease progression are not yet defined. On the basis of our results, it is reasonable to state that host immunogenetic factors, reflected by HLA background, are important determinants of HTLV-I disease outcome. The candidate, HLA class II genes have a significant role in regulating the immune response to infection and malignant transformation due to their function in presenting viral and other antigenic peptides to T lymphocytes (28) . The immunologic status of patients with ATL and HAM/TSP are distinct (29, 30) , with both diseases rarely occurring in the same individual (31) . Among carriers, those who develop ATL most likely acquire genetic defects in various viral (32) and tumor suppressor genes (33, 34) with progressive loss of immunologic control, resulting in malignant transformation. On the other hand, evidence suggests that HTLV-I carriers who subsequently develop HAM/TSP have an activated immune response with central nervous system damage mediated by high levels of HTLV-I-specific cytotoxic T lymphocytes (35) . Other important determinants of disease outcome include age at time of infection and route of virus transmission.
Several HLA class II alleles were associated with HTLV-I infection in the Jamaican population. The HTLV-I carrier state was distinguished from HTLV-I negative control subjects by two significant antigens, DR15 and DQ1. These antigens were in linkage disequilibrium and DR15 was always detected in the presence of DQ1. DQ1 was significant, even after adjustment for multiple comparisons of antigens with the conservative Bonferroni's correction. Study participants were carefully selected to prevent obscuring true HLA associations ascribed to HTLV-I infection from genetic differences, because populations in Jamaica and other parts of the Caribbean are known to be heterogeneous, consisting of different ethnic groups with racial admixture of native Amerindian, Caucasian, and African descent (36) . In our assessment of the immune response to virus, using antibody titers, there were no differences in antibody titer levels among carriers with and without DR15 and/or DQ1. The corresponding alleles by DNA typing, DRB1*1501 and DQB1*0602, have been associated with the low immune response profile characteristic of patients with ATL (37). In a previous report, HLA class I alleles, A36 and B18, were found to be increased among patients with ATL compared with HTLV-I carriers in a population of African descent, however, no differences in serologically determined class II alleles were identified (38) . Similarly, there were no significant differences in class II allele frequencies between ATL patients and HTLV-I carriers in the current study. There were corresponding differences in allele frequencies (DRB1*1101, DRB1*1501, and DQB1*0602) between these groups and patients with HAM/TSP, suggesting that the alleles identified were as follows: 1) representative of the carrier state and infection or 2) indicative of carriers at risk for progression to ATL but not HAM/ TSP. We found several alleles with increased frequency among patients with HAM/TSP although they did not approach statistical significance, possibly due to our modest sample size. In contrast to these findings, several class II alleles have been shown to be increased among patients with HAM/TSP that are unique to endemic Japanese populations (37) .
A comparison of results with those from Japan revealed that similar patterns of disease association were identified for DRB1*1501 and DQB1*0602 but not for DRB1*1101. The DRB1*1101 allele had a lower frequency (2.1%) in the Japanese population compared with West African (Senegalese) and North American Blacks (9.4% and 8.2%, respectively) in other reports (39) . On the other hand, the DR15-DQ1 haplotype has been associated with ATL and HAM/TSP in Japan (37) . With DNA typing, ATL was characterized by DRB1*1501-DQB1*0602, while HAM/ TSP was characterized by DRB1*1502-DQB1*0601 (37) . Thus, this haplotype may prove useful as a disease marker across racial groups, since it is a common haplotype among Asians, Caucasians, and African lineages (40) . Together, these observations suggest that there may be common haplotypes shared by individuals at risk for HTLV-I-related disease. Additionally, this same haplotype has been identified among Hispanic populations at risk for human papillomavirus type 16-associated cervical neoplasia (41), suggesting that a similar immunogenetic background may be implicated in immunologic control with several viral-related cancers. These intriguing observations require further investigation. Finally, this exploratory analysis will require subsequent confirmation with additional studies of association or family studies of HTLV-I-related disease.
